Novartis报告说,Kesimpta大大降低了复发率,并阻止了重病患者重覆治疗的步伐,超过90%的人多年来实现了NEDA-3。 Novartis reports Kesimpta significantly reduces relapses and halts progression in relapsing MS patients, with over 90% achieving NEDA-3 over years.

诺瓦蒂斯公司在2025年欧洲TRIMS会议上报告了Kesimpta(ofatumab)在治疗复发多发性硬化症方面取得的积极结果。 Novartis reported positive results for Kesimpta (ofatumumab) in treating relapsing multiple sclerosis at the ECTRIMS 2025 conference. 两项研究的数据表明,转而采用口服疗法的病人,如fingolimod或fummarates,年复发率非常低,为0.06,90%以上的人实现了NEDA-3,没有复发,没有新的MRI损伤,没有残疾升级——超过96周。 Data from two studies showed that patients switching from oral therapies like fingolimod or fumarates had a very low annual relapse rate of 0.06 and over 90% achieved NEDA-3—no relapses, no new MRI lesions, and no disability progression—over 96 weeks. 在一项长期研究中,90%以上的治疗-护理病人将NEDA-3保持了长达7年的状态。 In a long-term study, more than 90% of treatment-naive patients maintained NEDA-3 status for up to seven years. Kesimpta,每月自行注射的抗CD20抗体,目标是B细胞,已在92多个国家获得批准,截至2025年8月,治疗的病人超过15万。 Kesimpta, a monthly self-injected anti-CD20 antibody, targets B-cells and has been approved in over 92 countries, with more than 150,000 patients treated as of August 2025.